Subjects: CCA, TDS, OTC, FVT
HedgePath Pharmaceuticals, Inc. to Webcast, Live, at VirtualInvestorConferences.com October 5
Company invites individual and institutional investors as well as advisors to attend interactive real-time virtual VirtualInvestorConferences.com
TAMPA, Fla., Sept. 28, 2017 /PRNewswire/ -- HedgePath Pharmaceuticals, Inc. (OTCQX: HPPI), based in Tampa, a clinical stage biopharmaceutical company that discovers, develops and plans to commercialize innovative therapeutics for patients with cancer, today announced that Nicholas Virca, President and Chief Executive Officer, will present live at VirtualInvestorConferences.com on October 5, 2017.
DATE: Thursday, October 5, 2017
TIME: 3:00 pm ET
LINK: https://tinyurl.com/1005prepr
This will be a live, interactive online event where investors are invited to ask the company questions in real-time - both in the presentation hall as well as the association's "virtual trade booth." If attendees are not able to join the event live on the day of the conference, an on-demand archive will be available for 90 days.
It is recommended that investors pre-register and run the online system check to save time and receive event updates.
Learn more about the event at www.VirtualInvestorConferences.com.
Recent Company Highlights
- HedgePath Pharmaceuticals, Inc. up-listed to the OTCQX market in December 2016.
- Currently in Phase 2(b) skin cancer trial
- Future testing planned for lung and prostate cancer
- Received Orphan Drug Designation for its first anti-cancer indication
About HedgePath Pharmaceuticals, Inc.
HedgePath Pharmaceuticals, Inc. (OTCQX:HPPI) is a clinical stage biopharmaceutical company that is seeking to repurpose the FDA approved antifungal pharmaceutical itraconazole as a potential treatment for cancer. HPPI is the exclusive U.S. licensee of a patented formulation of itraconazole, called SUBA-ItraconazoleTM, which clinical studies have shown to have greater bioavailability than generic itraconazole. The Hedgehog signaling pathway is a major regulator of cellular processes in vertebrates, including cell differentiation, tissue polarity and cell proliferation. Based on published research, HPPI believes that inhibiting the Hedgehog pathway could delay or possibly prevent the development of certain cancers in humans. Leveraging research undertaken by key investigators in the field, HPPI is currently testing the drug in a Phase 2(b) clinical trial to treat basal cell carcinoma in patients with Basal Cell Carcinoma Nevus Syndrome, also known as BCCNS or Gorlin Syndrome. HPPI is headquartered in Tampa, Florida. For more information, please visit www.hedgepathpharma.com.
About VirtualInvestorConferences.com
Since 2010, VirtualInvestorConferences.com, created by BetterInvesting (NAIC) and PRNewswire, has been the only monthly virtual investor conference series that provides an interactive forum for presenting companies to meet directly with investors using a graphically-enhanced online platform.
Designed to replicate the look and feel of location-based investor conferences, Virtual Investor Conferences unites PR Newswire's leading-edge online conferencing and investor communications capabilities with BetterInvesting's extensive retail investor audience network.
SOURCE HedgePath Pharmaceuticals, Inc.
These press releases may also interest you
|
News published on and distributed by:
